HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.
about
Targeting Protein-Protein Interactions in the HIF SystemPHD2: from hypoxia regulation to disease progressionThe systemic nature of CKD.Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease.Hypoxia Inducible Factor 1: A Urinary Biomarker of Kidney DiseaseTargeting iron metabolism in drug discovery and deliveryStructural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases.Renal Hypoxia in CKD; Pathophysiology and Detecting Methods.Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.Boosting the hypoxic response in myeloid cells accelerates resolution of fibrosis and regeneration of the liver in mice.Investigational therapies for renal disease-induced anemia.A mechanistic link between renal ischemia and fibrosis.Hypoxia in Atherogenesis.Systems biology of oxygen homeostasis.The EGLN-HIF O2-Sensing System: Multiple Inputs and Feedbacks.Treatment of renal anemia: Erythropoiesis stimulating agents and beyond.Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.William Kaelin, Peter Ratcliffe, and Gregg Semenza receive the 2016 Albert Lasker Basic Medical Research Award.Cyclosporin a induces renal episodic hypoxia.Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase.Hypoxia-inducible factor prolyl-4-hydroxylase-1 is a convergent point in the reciprocal negative regulation of NF-κB and p53 signaling pathways.Transcriptional regulators of redox balance and other homeostatic processes with the potential to alter neurodegenerative disease trajectory.Induction of erythropoietin gene expression in epithelial cells by chemicals identified in GATA inhibitor screenings.Regulation of immunity and inflammation by hypoxia in immunological niches.Forkhead box O3 (FoxO3) regulates kidney tubular autophagy following urinary tract obstruction.miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target.Mechanisms of erythrocyte development and regeneration: implications for regenerative medicine and beyond.lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls.Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia.Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials.Immunometabolism: Oxygen sensing and cell metabolism in inflammation.Membrane traffic control by hypoxia.Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.Skin Sodium and Hypertension: a Paradigm Shift?Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers
P2860
Q26753176-B215775A-F1E7-4ED0-B22C-B290B3068201Q28069316-32A0410E-BEE7-4C07-BADC-57136DF26095Q30234695-A2CA0EAE-6099-4119-8617-65A805E42530Q33633674-BE15C20B-1458-49F4-ACAC-01B5AC8C507CQ33648040-8C8DF0C6-EBA1-42F0-899C-B91F685AEB48Q33757232-E54829E8-0110-41BD-B803-304BED86C7DDQ34538526-2996E862-C107-4AC6-957B-83186E2E0059Q37653803-03F29574-40D9-4B89-A21D-5EAC008729BBQ37705646-2EF0F7CA-AD96-4EAB-8C8F-9AC8CD519AF2Q37716500-AF807B40-F1AB-4DBB-B664-68F03AD8745AQ38819455-31C2B9AA-52DD-4D16-A3B1-9886858D594DQ38903388-E94D06B8-B56E-40A7-A181-BB286D919C4BQ38939115-1E13BD10-5A08-4E0A-8F5E-B83487594E9CQ39145122-90CF0B67-D269-4EFB-B630-1F5269036590Q39378738-B297FBC4-4855-4EA5-9DB3-30D8651CC660Q41387413-93CD4438-B53C-4D79-BCBF-AD6833835F90Q41652333-A28AF376-046A-4AAA-880F-C69C5673F299Q42042945-C90E55A2-E8BE-404D-A8F4-995571DDF38DQ42373787-5FAF6342-9181-4D87-928C-BD8208C470BBQ45858755-1B595B31-8666-43FB-8A17-743F4C137DDEQ45948669-97B7EEC1-A5AB-40B1-B74D-91BA11A2EABAQ47099652-96155BCC-2C13-4F87-A5C0-D4D2AE8F16EAQ47112569-F655DE1C-7B06-4505-AA12-CD1CAC549447Q47152282-5E8C2C87-7DE0-4E06-B466-5323FD4FBBCFQ47634204-8EE5E387-8F39-436D-B3A1-E34EC0BA73A1Q47708732-00EC8FFA-0326-4B17-9155-F27354ED6F00Q47834186-6C143ABF-1EC5-41EC-9725-8F00D3596A69Q48136998-AE3EED08-34D5-4FC7-9341-C8A8433E3EDEQ48268381-EDEDA135-DC93-4D64-B2A7-94FD81395E59Q48319000-D4BA0854-3BCF-4157-B3D9-373842F4ACC3Q48563617-9158D903-7C82-4FA0-9095-8748CFD64360Q49176400-684770A1-8FE5-4DEA-A230-3A8C16229686Q50052760-59E6285A-F134-4D15-8C4C-881C77C32ED5Q50073082-CBC83EEC-2F3D-44E7-97C1-D4450AD1B7F7Q51034301-B591C396-1CD7-4E95-9FE2-5368A5CD8411Q52683262-D4A3D151-82D8-48CA-9CF4-495250A62E5CQ58742915-388C3196-7CB1-4F9D-A78D-A0E75AC0BC51Q58765839-A57D9613-EE8D-4F1F-BB3C-85D985D7A4CC
P2860
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.
@en
type
label
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.
@en
prefLabel
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.
@en
P2860
P356
P1476
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.
@en
P2093
Kai-Uwe Eckardt
P2860
P2888
P304
P356
10.1038/NRNEPH.2015.193
P407
P577
2015-12-14T00:00:00Z
P6179
1045801609